FOXP3 and vitiligo: Interestingly, we found a significant decrease in FOXP3 levels in lesional skin when compared to perilesional skin (p = 0.007, SMD: -9.77 [-16.91, -2.62]) and nonlesional skin (p = 0.04, SMD: -1.01 [-1.95, -0.06]) in vitiligo patients (Figure S1a, b).